Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
absent, accomplished, adhesion, Aerie, Agile, ago, agonist, Allentown, analyst, anesthesia, Anthony, assay, atrophy, attrition, Australian, baby, bachelor, Barbari, basal, BD, BDII, bed, Belding, Berkeley, BET, betamethasone, BETi, biomarker, BioPharma, blood, Boron, Bright, bromodomain, Bruno, Buyer, Caledonian, Cap, cell, cerdulatinib, CFO, Chilcott, clause, clobetasol, cloud, Cmax, collateral, comfort, commute, condensed, Cone, confidence, consecutive, contendere, conviction, Cook, Cooley, Corectim, CPA, cracked, crime, culminating, cytokine, deadline, debilitating, deep, deficiency, degradation, delgocitinib, delisted, delisting, depilated, Dermavant, Dickinson, difamilast, dinitrochlorobenzene, divest, divested, divesting, divestiture, DNCB, dorsal, Dundee, elasticity, Eli, embedded, Endo, ENT, epigenetic, escape, Eucrisa, evidenced, exhaustive, exploit, extinguishment, Farleigh, felony, fibrotic, filaggrin, float, Florham, FMX, Foote, footnote, forfeiting, FW, gene, glucocorticosteroid, Harsch, heal, healed, healing, hereunder, hydroalcoholic, hydrocortisone, Iain, ID, imiquimod, impede, implicated, Incyte, indictment, induction, InhiBET, InhiBETTM, Inline, Innoviva, InterMune, Intersect, intracellularly, Jose, Lafayette, Lambert, landscape, Lannett, lawyer, leaf, lebrikizumab, library, licensor, Lilly, Lincoln, LLOQ, logo, macular, mADI, Mahana, Master, matrix, median, melanin, melanocyte, melanosome, metabolite, mice, migration, misalign, mode, Muhlenberg, Mutya, myeloproliferative, neoplastic, nolo, ointment, Onset, Opzelura, OTC, ourpatent, Overview, Page, pan, pathology, PCT, PharMerica, Phytogen, pigment, plasma, plea, pledging, Polk, potent, prepay, Procept, proliferation, propionate, prorated, protracted, PTO, Quantified, recipient, refocusing, regain, regeneration, repair, revert, Rex, ruxolitinib, Satsuma, Scotland, Sharon, Shearman, Silicon, soft, soluble, Sonoma, spread, Sterling, steroid, streamlined, Stuart, sublicensable, sublicense, sublicensing, swelling, swollen, Syntex, Syracuse, tapinarof, tenure, terminology, thirty, Tigercat, tissue, TNF, Tofacitnib, topline, TPG, transcription, transcriptional, translucency, triamcinolone, Tribute, Tyler, unrestricted, unusual, upregulated, upregulation, vaccination, Valley, verification, Villanova, Virginia, visibility, vitiligo, Wardwell, warehouse, Warner, weigh, width, WNT, wrinkling, XELJANZ, YWCA, Zeronda
Removed:
abroad, addressed, al, allegation, allege, alternate, anxiety, attempted, Ball, bankruptcy, baseline, bound, brand, certified, charged, competitor, connected, consumed, convenience, coordinate, coordination, County, covenant, creating, declaration, deficit, dependence, dermatologic, devoted, diarrhea, dividing, drop, ease, educating, efficiently, element, exclusively, expended, frequency, genetic, geopolitical, identification, immigration, incident, infection, insolvency, institute, intensely, investigator, itching, Kingdom, Kristine, literature, living, managerial, Mateo, McKay, medicine, Merck, merit, minimal, MNLO, mouth, nausea, negotiated, novelty, numerical, older, ordered, owe, Paediatric, parallel, patented, performed, perpetual, post, predicted, prefer, preferential, prohibiting, proportion, pruritic, purported, putative, quantity, randomized, recoverable, recruit, refine, reimbursable, reliably, removed, renal, rent, respiratory, reveal, safeguard, scaly, scarring, seizure, sharing, show, sponsored, stable, strictly, supplier, survey, Taiwan, tolerability, tolerated, tract, traded, training, traveling, trend, unapproved, uncured, undergoing, unrest, upper, venture, visit, vital, voluntarily, vomiting, vulnerability, week, widespread, withheld, wrong
Filing tables
Filing exhibits
Related press release
VYNE similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of VYNE Therapeutics Inc. (the "Company") for the year ended December 31, 2021 as filed with the Securities and Exchange Commission (the "Report"), I, David Domzalski, President and Chief Executive Officer and principal executive officer, hereby certify as of the date hereof, solely for the purposes of 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: March 17, 2022 | By: | /s/ David Domzalski | |||||||||
| David Domzalski | |||||||||||
| Chief Executive Officer | |||||||||||
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.